

Interaction Report**Report ID:****Date Produced:** 14 November 2021**Antiretroviral Treatment**Bictegravir/ Emtricitabine/Tenofovir alafenamide
(BIC/FTC/TAF)**Co-medications**Cyclophosphamide
Doxorubicin
Prednisolone
Rituximab
Vincristine

This report lists the summaries of potential interactions (i.e. "red", "amber" and "yellow" classifications) for the drugs in the table above.

Interactions with a "green" or "grey" classification (i.e. no clinically significant interaction or no clear data) have been checked and are listed at the end of this report, but summaries are not shown.

For full details of all interactions, see www.hiv-druginteractions.org.

Description of the interactions**No clinically significant interaction expected (GREEN)**

Bictegravir/ Emtricitabine/Tenofovir alafenamide (BIC/FTC/TAF) + Cyclophosphamide

Bictegravir/ Emtricitabine/Tenofovir alafenamide (BIC/FTC/TAF) + Rituximab

Bictegravir/ Emtricitabine/Tenofovir alafenamide (BIC/FTC/TAF) + Vincristine

Bictegravir/ Emtricitabine/Tenofovir alafenamide (BIC/FTC/TAF) + Doxorubicin

Bictegravir/ Emtricitabine/Tenofovir alafenamide (BIC/FTC/TAF) + Prednisolone